Retrospective Analysis Of Lung Cancer Patients In Five Years

Objective:This study conducted a retrospective analysis of lung cancer inpatients in The Affiliated Hospital of Inner Mongolia Medical University from 2013 to 2017,in order to understand the disease characteristics,changes and diagnosis and treatment of lung cancer patients in the past 5 years.Methods: The general situation,clinical data and treatment status of inpatients with lung cancer during 2013-2017 were collected by electronic medical record system.SPSS 20.0 was used for statistical analysis.The qualitative data were expressed as cases and percentages.The chi-square comparison was used for comparison of count data.test.Results: From 2013 to 2017,a total of 3,856 lung cancer patients were admitted to our hospital.The number of cases each year was: 662,676,754,859,and 905,showing an upward trend.There were 2917 male patients and 939 female patients,and the gender ratio was 3.11: 1.The median age of onset was 67 years,and the peak age range was 65-69 years.1514 patients with adenocarcinoma accounted for 39.9%,1378 patients with squamous cell carcinoma accounted for 36.6%,802 patients with small cell carcinoma accounted for 21.1%,adenosquamous cell carcinoma and large cell carcinoma were rare,and the main pathological type of men was squamous cell carcinoma(43.55 %),Women are mainly adenocarcinoma(66.70%).The main pathological method was fiber bronchoscope(55.81%).Among all patients,45.82%(1767/3856)had no smoking history,41.65%(1606/3856)had smoking status,and12.53%(483/3856)had smoking status;the proportion of males in the smoking group(including smoking and previous smoking)The proportion of women in the non-smoker group was significantly higher than that in the non-smoker group(P<0.05);the proportion of adenocarcinoma in the non-smoker group was significantly higher than that in the smoking group,and the proportion of squamouscell carcinoma in the smoking group was significantly higher than that in the non-smoker group(P<0.05).In all patients,56.51%(2179/3856)of the primary lesions were located in the right lung,41.70%(1608/3856)of the left lung,and 1.56%(60/3856)of the bilateral lung involvement.The remaining 9 lesions were located in the mediastinum and trachea(0.23%);common lung cancer imaging manifestations:hilar mass shadows(13.9%),nodular shadows(23.8%),peripheral mass shadows(43.6%),peripheral patchy shadows(11.5%),hollow shadows(2.3%),Others(4.6%).The constituent ratios of stage 0-IV in the first visit of TNM stage were: 0.14%,8.52%,8.89%,29.18%,53.26%.Patients with stage 0 to Ⅱ are the first choice for surgery-based comprehensive treatment(accounting for 58.96%),and patients with stage Ⅲ to Ⅳ are the first choice for chemotherapy alone(accounting for 51.04%).Non-small cell lung cancer gene submission rates from 2013 to 2017: 5.46%,6.91%,11.97%,16.52%,20.97%,of which 9.69%,13.06%,23.94%,29.36%,39.44% for adenocarcinoma,and 0.82%,0.76%,1.11%,1.45%,2.45%;adenocarcinoma gene mutation rate was 52.99%,squamous cell carcinoma gene mutation rate was 12.5%;EGFR(86.41%)was the most common mutation gene,followed by ALK(5.98%),The remaining rare mutations are KRAS,BRAF,c-MET,KIT,PIK,HER-2;the ratio of EGFR gene mutation sites: 19-point mutation(46%),21-point mutation(38%),20-point mutation(11 %),18-point mutation(5%).Within 5 years,the rate of targeted therapy for non-small cell lung cancer gene-positive patients reached 83.70%.Conclusion: From 2013 to 2017,the gender ratio of male and female lung cancer patients in The Affiliated Hospital of Inner Mongolia Medical University was 3.11,and the peak age range was 65-69 years.Adenocarcinoma is the most common pathological type,followed by squamous cell carcinoma and small cell carcinoma.Cases were taken mainly by bronchoscope.The majority of men in the smoking group were predominantly pathological in squamous cell carcinoma,while the majority of women in the non-smoker group were predominantly pathological in adenocarcinoma.The most common imaging findings of lung cancer are shadows of surrounding masses,nodules,and hilar masses.66.48% of lung cancer patients were in advanced stage(including stage IIIB and stage IV)at the time of first diagnosis.The rate oflung adenocarcinoma gene submission is increasing year by year.The most common mutant gene of non-small cell lung cancer is EGFR mutation.The common mutation sites are 19-point mutation(46%)and 21-point mutation(38%).The targeted treatment rate of small cell lung cancer patients reached 83.70%.